[CPXX] Celator Pharmaceuticals Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 1.3 B

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 30.24 Change: 0 (0%)
Ext. hours: 30.24 Change: 0 (0%)

chart CPXX

Refresh chart

Description: Celator Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies to treat cancer. Its proprietary drug ratio technology platform, CombiPlex, enables the rational design and rapid evaluation of optimized combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver enhanced anti-cancer activity. The company?s product pipeline includes CPX-351, a liposomal formulation of cytarabine:daunorubicin, which is in Phase III studies for the treatment of acute myeloid leukemia; and CPX-1, a liposomal formulation of irinotecan:floxuridine that has completed Phase II study for the treatment of colorectal cancer. Its preclinical stage product candidates comprise CPX-571, a liposomal formulation of irinotecan:cisplatin; and CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation for in vitro and in vivo study. The company was founded in 1999 and is headquartered in Ewing, New Jersey.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-48.83% ROE-97.4% ROI
Current Ratio8.05 Quick Ratio Long Term Debt/Equity0.45 Debt Ratio0.24
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities5 M Cash From Investing Activities-20 K Cash From Operating Activities-4.49 M Gross Profit
Net Profit-4.71 M Operating Profit-4.38 M Total Assets35.5 M Total Current Assets33.96 M
Total Current Liabilities4.22 M Total Debt15.17 M Total Liabilities17.7 M Total Revenue
Technical Data
High 52 week30.31 Low 52 week1.19 Last close30.24 Last change0%
RSI68 Average true range2.2 Beta0.01 Volume
Simple moving average 20 days0.15% Simple moving average 50 days21.83% Simple moving average 200 days
Performance Data
Performance Week-0.03% Performance Month0.43% Performance Quart116% Performance Half2091.3%
Performance Year-91.89% Performance Year-to-date0% Volatility daily0.1% Volatility weekly0.23%
Volatility monthly0.47% Volatility yearly1.62% Relative Volume0% Average Volume2.85 M
New High New Low

News

2017-02-07 16:45:06 | Actinium Pharmaceuticals Is Better Than Celator

2016-12-19 09:10:00 | The Best Biopharma CEOs of 2016 Are...

2016-11-03 16:34:42 | Hercules Announces Strong Third Quarter Financial Results With $0 ...

2016-08-17 09:33:10 | RA Capital’s Top Q2 Performers; Predicts Big Things Ahead for Pharma Stocks

2016-07-14 10:06:47 | How Can Celator’s Portfolio Complement Jazz Pharmaceuticals?

2016-07-13 15:51:35 | A Look at Jazz Pharmaceuticals’ Celator Acquisition Deal

2016-07-13 15:51:21 | Why Did Jazz Fall after Celator Acquisition Announcement?

2016-07-12 16:02:40 | CELATOR PHARMACEUTICALS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisi

2016-07-12 02:03:04 | Jazz Pharmaceuticals plc Announces Results of Tender Offer to Purchase All of The Outstanding Shares of Common Stock of Celator Pharmaceuticals, Inc.

2016-07-12 01:50:00 | Jazz Pharmaceuticals plc Announces Results of Tender Offer to Purchase All of The Outstanding Shares of Common Stock of Celator Pharmaceuticals, Inc.

2016-07-07 13:33:42 | Steven Cohen Hits Another Home Run in Oncology

2016-06-27 08:21:00 | Why Celator Pharmaceuticals Is Up 1,610% in 2016

2016-06-27 00:09:00 | Jazz Pharmaceuticals Announces Expiration of HSR Waiting Period for Proposed Celator Pharmaceuticals, Inc. Acquisition

2016-06-14 22:09:03 | Yale Joins PTX’s Phase 1b/2 AML Clinical Trial

2016-06-14 09:02:16 | CELATOR PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits

2016-06-14 07:00:00 | Celator Pharmaceuticals® Announces Positive Results in Patients with FLT3 Mutation from the Phase 3 Trial in High-Risk Acute Myeloid Leukemia

2016-06-13 19:00:00 | INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Celator Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional Information

2016-06-08 18:36:00 | SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Celator Pharmaceuticals, Inc. - CPXX

2016-06-06 17:13:14 | CELATOR PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits

2016-06-06 07:00:00 | Celator Pharmaceuticals® Presented Phase 3 Trial Results in Patients with High-Risk Acute Myeloid Leukemia Demonstrating VYXEOS™ CPX-351 Significantly Improved Overall Survival

2016-06-04 09:40:00 | Why Celator Pharmaceuticals Shares Skyrocketed 100% in May

2016-06-03 18:21:00 | Celator Pharmaceuticals, Inc. Acquisition May Not Be in the Best Interests of CPXX Shareholders

2016-06-03 09:46:59 | The market is looking for a Celator spoiler bid

2016-06-02 13:21:00 | CELATOR PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Jazz Pharmaceuticals plc

2016-06-02 09:11:00 | SHAREHOLDER ALERT: Law Offices of Marc S. Henzel Announces Investigation into the proposed sales and mergers of American Capital Ltd., Celator Pharmaceuticals, Inc., Demandware Inc., FEI Company, Marketo Inc., SciQuest, Inc., Textura Corporation, Westar E

2016-06-02 09:11:00 | SHAREHOLDER ALERT: Law Offices of Marc S. Henzel Announces Investigation into the proposed sales and mergers of American Capital Ltd., Celator Pharmaceuticals, Inc., Demandware Inc., FEI Company, Marketo Inc., SciQuest, Inc., Textura Corpor

2016-06-01 16:59:40 | Celator Pharmaceuticals, Inc. :CPXX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016

2016-06-01 15:11:08 | Jazz Securities Limited -- Moody's affirms Jazz's Ba3 CFR; Outlook to Negative

2016-06-01 11:18:00 | CELATOR PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

2016-06-01 10:55:00 | CPXX: Jazz Acquires Celator for $30.25 per Share

2016-05-31 03:42:04 | Jazz Pharmaceuticals And Celator Pharmaceuticals Announce Agreement For Jazz Pharmaceuticals To Acquire Celator For $30.25 Per Share

2016-04-12 19:22:09 | Investor Presentation – April 2016

2016-03-28 13:19:25 | Trending Stocks To Have On Your Watch-list Monday 3/28/16